Giovanna Marrapese
机构: Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy
每年引用次数
引用次数
引用: 4,200
H-指数: 16
I10-指数 : 17
出版物: 38
112P Clinicopathological characterization of MTAP-altered metastatic gastrointestinal tumors
G Mauri , G Patelli , L Roazzi , A Amatu
Annals of Oncology 33 S1418
2022
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer Discov. 2017; 7: 400–409. doi: 10.1158/2159-8290
A Drilon , S Siena , SI Ou , M Patel
Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A Cribriform Cancer Metastatic to Liver: Case Report and Literature Review DOI 10 000502572 -000502572
131
2019
RXDX-101, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations
FGM De Braud , L Pilla , M Niger , S Damian
Annals of Oncology 25 iv148 -iv148
14
2014
Copy number increase of the epidermal growth factor receptor gene is associated with clinical response of colorectal cancer to ANTI-EGFR antibody therapy
M Moroni , S Veronese , S Benvenuti , G Marrapese
ANNALS OF ONCOLOGY 16 7 -7
1
2005
Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within clinical studies based on individual molecular alterations at Niguarda Cancer Center
A Sartore-Bianchi , A Amatu , S Stabile , F Tosi
Annals of Oncology 26 vi39 -vi39
2015
TRKA expression and NTRK1 gene copy number across solid tumors
G Mauri , E Valtorta , A Sartore-Bianchi , G Cerea
Annals of Oncology 28 v600 -v600
2017
MULTI-DETERMINANTS ANALYSIS OF MOLECULAR ALTERATIONS FOR PREDICTING CLINICAL BENEFIT TO EGFR-TARGETED MONOCLONAL ANTIBODIES IN COLORECTAL CANCER
MF Frattini , AS Sartore-Bianchi , FD Di Nicolantonio , MN Nichelatti
ANNALS OF ONCOLOGY 21 I15 -I15
2010
Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies.
Angelo Vanzulli , Giovanna Marrapese , Simona Secondino , Paolo Pedrazzoli
I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 1 ( 4)
2002
Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation
Alessio Amatu , Andrea Sartore-Bianchi , Katia Bencardino , Andrea Cassingena
Current Colorectal Cancer Reports 8 ( 4) 272 -276
2
2012
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Andrea Sartore-Bianchi , Elio Gregory Pizzutilo , Giovanna Marrapese , Federica Tosi
Expert Review of Anticancer Therapy 20 ( 5) 333 -341
9
2020
Phase II study of dacarbazine for metastatic colorectal cancer: Final results with MGMT analysis.
Alessio Amatu , Andrea Sartore Bianchi , Catia Moutinho , Katia Bencardino
Journal of Clinical Oncology 31 3581 -3581
2013
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon , Salvatore Siena , Sai-Hong Ignatius Ou , Manish Patel
Cancer Discovery 7 ( 4) 400 -409
376
2017
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore‐Bianchi , Alessio Amatu , Luca Porcu , Silvia Ghezzi
Oncologist 24 ( 10) 1395 -1402
83
2019
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi , Livio Trusolino , Cosimo Martino , Katia Bencardino
Lancet Oncology 17 ( 6) 738 -746
776
2016
Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Andrea Sporchia , Giulio Cerea , Maria Maugeri , Tiziana Cipani
Current Cancer Therapy Reviews 3 ( 4) 249 -254
2007
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Mauro Moroni , Silvio Veronese , Silvia Benvenuti , Giovanna Marrapese
Lancet Oncology 6 ( 5) 279 -286
1,152
2005
TRKA expression and NTRK1 gene copy number across solid tumours.
Gianluca Mauri , Emanuele Valtorta , Giulio Cerea , Alessio Amatu
Journal of Clinical Pathology 71 ( 10) 926 -931
8
2018
Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer
Federica Tosi , Andrea Sartore-Bianchi , Sara Lonardi , Alessio Amatu
Clinical Colorectal Cancer 19 ( 4) 256 -262
47
2020
Alka-372-001: First-in-human, phase I study of entrectinib - an oral pan-trk, ROS1, and ALK inhibitor - in patients with advanced solid tumors with relevant molecular alterations.
Filippo G. De Braud , Monica Niger , Silvia Damian , Benedetta Bardazza
Journal of Clinical Oncology 33 2517 -2517
31
2015
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
Andrea Sartore-Bianchi , Alessio Amatu , Erica Bonazzina , Stefano Stabile
Targeted Oncology 12 ( 4) 525 -533
9
2017